Our aim was to investigate the efficacy and safety of
etanercept as adjuvant to interferon and ribavirin
in treatment-naive patients with HCV. METHODS: Double-blind, randomized, placebo controlled trial. Fifty patients with chronic HCV were randomly assigned to receive interferon alfa-2b and ribavirin with either etanercept or placebo for 24 weeks. The main outcome measure was the absence of HCV RNA at 24 weeks, the on treatment response at the end of the etanercept randomization period.